Rome – By now the figure is more than full-blown: multinationals in the pharmaceutical sector are increasingly turning to the Italian experience, so much so that the 10% of pharmaceutical raw materials are produced and exported from our country.
Let's talk about a market that produces a turnover, in Italy alone, of 4.3 billion dollars, as not only AschimFarma and Aifa have recently highlighted, but also the most important pharmaceutical companies properly united under the name of Big Pharma, increasingly interested in Italian production. Nothing to do with the economic convenience that low-cost Asian countries offer. On the contrary, the result is the result of technical expertise, safety and quality, purity, timing and package, i.e. elements that have always distinguished made in Italy in this very delicate sector which currently exports, as evidenced by the recent study report carried out by the University of Turin, the 85% of active pharmaceutical ingredients.
It can definitely be defined as a virtuous circle of excellence, among which they represent a significant importance the planing and realization of scientific laboratories designed to meet the multiple needs of research. “We are talking about places that must necessarily be synonymous with safety, sustainability and quality”, as he points out Giancarlo De Matthaeis, president of Labozeta Spa, a leading company in the design and construction of scientific laboratories since 1983. "The know-how that Italy has achieved in this field, through strict compliance with current regulations, the particular attention of those who live chemical and pharmaceutical laboratories, the consequent design and sustainable improvements have undoubtedly favored a further increase in quality standards that have now reached truly enviable levels”.
“Of course, there is still a lot to do in this sector, above all in terms of projects capable of synergizing the various excellences and potentials that our country offers, according to an increasingly circular and therefore sustainable economy. Certainly – concludes De Matthaeis – the future is projecting us towards the so-called industry 4.0, in which new scenarios will inevitably open up in the production of goods and services that will bring new lifeblood to innovation, development and above all to greater vertical integration”.
OMAR – Author: Redaction
Related news: Pfizer, the Catania plant is the European center for penicillins of the entire American group
ISTAT. Production of basic pharmaceutical products and pharmaceutical preparations +6.3% in October
